X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-07-31 | PGEN | Precigen, Inc. | Thomasian Harry Jr. | CFO | S - Sale | $6.06 | -100,000 | 254,535 | -28% | -$606,000 | ||||||
| D | 2026-07-30 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $524.91 | -9,500 | 668,728 | -1% | -$4,986,594 | |||||
2026-07-29 | HCWB | Hcw Biologics Inc. | Wong Hing C | CEO, 10% | P - Purchase | $2.59 | +23,210 | 125,845 | +23% | +$59,998 | ||||||
2026-07-29 | HCWB | Hcw Biologics Inc. | Flowers Lee | SVP of Business Development | P - Purchase | $2.59 | +7,736 | 8,691 | +810% | +$19,998 | ||||||
2026-07-29 | HCWB | Hcw Biologics Inc. | Garrett Scott T | Dir | P - Purchase | $2.59 | +7,736 | 41,644 | +23% | +$19,998 | ||||||
2026-07-29 | PRTA | Prothena Corp Public Ltd Co | Kingston Anne Evans | Chief Strategy Officer | S - Sale | $8.47 | -7,662 | 55,782 | -12% | -$64,919 | ||||||
2026-07-29 | PRTA | Prothena Corp Public Ltd Co | Isaacs Michael John | GC, Company Sec. | S - Sale | $8.47 | -8,386 | 35,745 | -19% | -$71,055 | ||||||
| M | 2026-07-28 | MLPT | Maplight Therapeutics, Inc. | Catalyst4, Inc. | 10% | P - Purchase | $12.67 | +1,209,225 | 20,906,689 | +6% | +$15,314,794 | |||||
| D | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $23.38 | -2,845 | 44,927 | -6% | -$66,524 | |||||
| D | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $23.38 | -3,847 | 19,912 | -16% | -$89,954 | |||||
| D | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $23.38 | -3,847 | 121,338 | -3% | -$89,954 | |||||
2026-07-28 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | EVP, Chief Development Officer | S - Sale | $7.10 | -189 | 94,632 | 0% | -$1,342 | ||||||
| D | 2026-07-30 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $79.88 | -14,000 | 58,555 | -19% | -$1,118,320 | |||||
2026-07-29 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale | $81.36 | -2,850 | 174,693 | -2% | -$231,876 | ||||||
| D | 2026-07-29 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $522.37 | -9,500 | 668,728 | -1% | -$4,962,488 | |||||
| M | 2026-07-28 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.43 | +2,200 | 5,611,402 | 0% | +$29,555 | |||||
| D | 2026-07-27 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $34.95 | -200,000 | 1,613,063 | -11% | -$6,990,000 | |||||
2026-07-29 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO | S - Sale | $33.32 | -148,517 | 2,572,441 | -5% | -$4,947,888 | ||||||
2026-07-29 | VKTX | Viking Therapeutics, Inc. | Zante Greg | CFO | S - Sale | $33.47 | -21,217 | 212,204 | -9% | -$710,141 | ||||||
2026-07-29 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale | $33.47 | -18,217 | 422,760 | -4% | -$609,636 | ||||||
| M | 2026-07-27 | NXTC | Nextcure, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $4.98 | +17,608 | 393,266 | +5% | +$87,713 | |||||
2026-07-27 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $87.53 | -1,600 | 167,919 | -1% | -$140,048 | ||||||
2026-07-27 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale | $87.53 | -688 | 216,438 | 0% | -$60,221 | ||||||
2026-07-27 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $25.51 | -261,460 | 3,586,796 | -7% | -$6,670,769 | ||||||
2026-07-27 | MLTX | Moonlake Immunotherapeutics | Reich Kristian | Chief Scientific Officer | S - Sale | $20.00 | -1,100 | 2,746,587 | 0% | -$22,000 | ||||||
| D | 2026-07-27 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $20.00 | -1,000 | 51,776 | -2% | -$20,000 | |||||
2026-07-27 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $42.11 | -2,210 | 640,065 | 0% | -$93,061 | ||||||
2026-07-27 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.62 | +1,500 | 5,609,202 | 0% | +$20,430 | ||||||
2026-07-28 | MPLT | Maplight Therapeutics, Inc. | Cox Troy | Dir | P - Purchase | $9.52 | +15,620 | 23,484 | +199% | +$148,702 | ||||||
| D | 2026-07-28 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $526.73 | -9,500 | 668,728 | -1% | -$5,003,976 | |||||
| D | 2026-07-24 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale+OE | $12.02 | -13,100 | 244,972 | -5% | -$157,462 | |||||
2026-07-27 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.44 | +5,000 | 652,000 | +1% | +$17,200 | ||||||
| D | 2026-07-27 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $530.42 | -9,500 | 668,728 | -1% | -$5,038,971 | |||||
| M | 2026-07-23 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $11.65 | -25,000 | 819,798 | -3% | -$291,163 | |||||
| D | 2026-07-27 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $80.87 | -7,500 | 381,986 | -2% | -$606,525 | |||||
2026-07-23 | IRD | Opus Genetics, Inc. | Yerxa Benjamin R | Pres | S - Sale | $2.97 | -7,429 | 704,106 | -1% | -$22,064 | ||||||
2026-07-23 | IRD | Opus Genetics, Inc. | Schachle Joseph K | COO | S - Sale | $2.94 | -4,644 | 291,440 | -2% | -$13,653 | ||||||
2026-07-23 | IRD | Opus Genetics, Inc. | Magrath George | CEO | S - Sale | $2.95 | -9,475 | 1,731,869 | -1% | -$27,926 | ||||||
2026-07-23 | IRD | Opus Genetics, Inc. | Gagnon Robert E. | CFO | S - Sale | $2.95 | -7,783 | 584,375 | -1% | -$22,942 | ||||||
2026-07-27 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.37 | +3,188 | 647,000 | 0% | +$10,744 | ||||||
2026-07-24 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.73 | +3,000 | 643,812 | 0% | +$11,190 | ||||||
| D | 2026-07-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $531.74 | -9,500 | 668,728 | -1% | -$5,051,519 | |||||
| M | 2026-07-23 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.06 | +3,600 | 5,607,702 | 0% | +$47,018 | |||||
| AM | 2026-07-14 | GDTC | Cytomed Therapeutics Ltd | Choo Chee Kong | Dir, 10% | P - Purchase | $1.50 | +200,000 | 630,324 | +46% | +$300,000 | |||||
| D | 2026-07-23 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $106.07 | -10,700 | 492,982 | -2% | -$1,134,890 | |||||
| D | 2026-07-22 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $325.00 | -1,669 | 338,884 | 0% | -$542,425 | |||||
| D | 2026-07-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $528.58 | -9,500 | 668,728 | -1% | -$5,021,520 | |||||
| M | 2026-07-22 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $88.93 | -200,000 | 573,071 | -26% | -$17,786,409 | |||||
| M | 2026-07-14 | GDTC | Cytomed Therapeutics Ltd | Choo Chee Kong | Dir, 10% | P - Purchase | $1.50 | +200,000 | 630,324 | +46% | +$300,000 | |||||
| D | 2026-07-21 | MLYS | Mineralys Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale+OE | $26.87 | -7,438 | 38,400 | -16% | -$199,885 | |||||
| D | 2026-07-22 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $530.57 | -9,500 | 748,828 | -1% | -$5,040,380 | |||||
2026-07-21 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | GC | S - Sale | $1.76 | -573 | 82,194 | -1% | -$1,008 | ||||||
2026-07-21 | RANI | Rani Therapeutics Holdings, Inc. | Imran Mir A | Dir, 10% | P - Purchase | $0.69 | +36,000 | 24,853,526 | 0% | +$24,840 | ||||||
| D | 2026-07-21 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $80.59 | -3,500 | 153,902 | -2% | -$282,065 | |||||
| M | 2026-07-21 | MLTX | Moonlake Immunotherapeutics | Reich Kristian | Chief Scientific Officer | S - Sale | $20.02 | -52,448 | 2,747,687 | -2% | -$1,049,960 | |||||
| M | 2026-07-20 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $79.97 | -78,596 | 773,071 | -9% | -$6,285,250 | |||||
| DM | 2026-07-20 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale+OE | $315.29 | -109,713 | 50,493,512 | 0% | -$34,590,855 | |||||
| M | 2026-07-20 | PBLS | Parabilis Medicines, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $28.29 | +244,593 | 29,177,964 | +1% | +$6,919,551 | |||||
| D | 2026-07-21 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $532.24 | -9,500 | 668,728 | -1% | -$5,056,298 | |||||
2026-07-21 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $6.53 | -1,478 | 492,079 | 0% | -$9,651 | ||||||
2026-07-20 | SGMT | Sagimet Biosciences Inc. | Happel David | Pres, CEO | S - Sale | $7.76 | -64,051 | 741,570 | -8% | -$497,068 | ||||||
2026-07-20 | SGMT | Sagimet Biosciences Inc. | Rozek Elizabeth | Chief Legal, Admin. Officer | S - Sale | $7.76 | -10,545 | 224,414 | -4% | -$81,832 | ||||||
| D | 2026-07-20 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $30.34 | -105,000 | 24,353 | -81% | -$3,185,656 | |||||
2026-07-20 | SGMT | Sagimet Biosciences Inc. | Kemble George | Dir | S - Sale | $7.46 | -18,844 | 62,161 | -23% | -$140,529 | ||||||
| D | 2026-07-20 | AKTS | Aktis Oncology, Inc. | Herrmann Ken | Dir | S - Sale+OE | $24.56 | -4,856 | 0 | -100% | -$119,274 | |||||
| M | 2026-07-17 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.44 | +4,863 | 2,858,935 | 0% | +$11,866 | |||||
2026-03-27 | RANI | Rani Therapeutics Holdings, Inc. | Javadi Alireza | Chief Technical Officer | S - Sale | $0.78 | -386 | 9,380 | -4% | -$301 | ||||||
2026-07-17 | RANI | Rani Therapeutics Holdings, Inc. | Imran Talat | CEO | P - Purchase | $0.72 | +35,000 | 469,736 | +8% | +$25,193 | ||||||
2024-12-27 | RANI | Rani Therapeutics Holdings, Inc. | Imran Talat | CEO | S - Sale | $1.41 | -8,014 | 434,736 | -2% | -$11,300 | ||||||
2026-07-20 | MLTX | Moonlake Immunotherapeutics | Reich Kristian | Chief Scientific Officer | S - Sale | $20.09 | -43,700 | 2,800,135 | -2% | -$877,933 | ||||||
| D | 2026-07-20 | JNJ | Johnson & Johnson | Broadhurst Vanessa | EVP, Global Corp Affairs | S - Sale+OE | $251.27 | -23,054 | 23,003 | -50% | -$5,792,686 | |||||
| D | 2026-07-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $52.64 | -6,018 | 46,054 | -12% | -$316,780 | |||||
| D | 2026-07-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | S - Sale+OE | $52.67 | -5,000 | 25,000 | -17% | -$263,373 | |||||
| D | 2026-07-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $531.69 | -9,500 | 668,728 | -1% | -$5,051,035 | |||||
2026-07-20 | IMNN | Imunon, Inc. | Eylward Susan | GC, Corp Sec | S - Sale | $1.78 | -2,150 | 2,896 | -43% | -$3,830 | ||||||
2026-07-20 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.46 | +5,000 | 640,812 | +1% | +$17,300 | ||||||
2026-07-17 | PRQR | Proqr Therapeutics N.V. | Filius Bart | Dir | P - Purchase | $1.72 | +150,000 | 300,000 | +100% | +$257,925 | ||||||
| D | 2026-07-20 | MDGL | Madrigal Pharmaceuticals, Inc. | Sibold William John | Pres, CEO | S - Sale+OE | $547.30 | -2,500 | 209,329 | -1% | -$1,368,253 | |||||
| M | 2026-07-16 | FULC | Fulcrum Therapeutics, Inc. | Tang Kevin | 10% | P - Purchase | $3.55 | +167,616 | 7,080,945 | +2% | +$594,675 | |||||
| D | 2026-07-17 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $26.53 | -416 | 51,384 | -1% | -$11,036 | |||||
2026-07-20 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $3.47 | +12,000 | 986,967 | +1% | +$41,640 | ||||||
| D | 2026-07-17 | AKTS | Aktis Oncology, Inc. | Herrmann Ken | Dir | S - Sale+OE | $25.21 | -3,065 | 0 | -100% | -$77,259 | |||||
| D | 2026-07-16 | CBIO | Crescent Biopharma, Inc. | Fairmount Funds Management LLC | Dir, 10% | P - Purchase | $14.50 | +853,450 | 3,601,316 | +31% | +$12,375,025 | |||||
| D | 2026-07-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $537.05 | -9,500 | 668,728 | -1% | -$5,101,939 | |||||
2026-07-17 | LYEL | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd | 10% | S - Sale | $13.70 | -10 | 2,857,480 | 0% | -$137 | ||||||
2026-07-15 | MLTX | Moonlake Immunotherapeutics | Reich Kristian | Chief Scientific Officer | S - Sale | $20.01 | -16,105 | 2,843,835 | -1% | -$322,261 | ||||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Gillis Jonathan | CAO, Interim CFO | S - Sale | $37.12 | -36,979 | 144,240 | -20% | -$1,372,668 | |||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Kreitzer Anatol | Chief Discovery Officer | S - Sale | $37.09 | -36,284 | 174,906 | -17% | -$1,345,894 | |||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Kroeger Christopher A. | CEO | S - Sale | $36.87 | -147,639 | 1,347,645 | -10% | -$5,443,722 | |||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | S - Sale | $36.88 | -18,267 | 224,462 | -8% | -$673,636 | |||||
2026-07-16 | LYEL | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd | 10% | S - Sale | $13.73 | -10 | 2,857,490 | 0% | -$137 | ||||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Hanson Kristopher | GC | S - Sale | $36.82 | -16,508 | 145,823 | -10% | -$607,870 | |||||
| D | 2026-07-17 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale+OE | $4.05 | -24,109 | 797,554 | -3% | -$97,641 | |||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Foff Erin Pennock | Chief Medical Officer | S - Sale | $36.78 | -47,158 | 298,901 | -14% | -$1,734,490 | |||||
| D | 2026-07-17 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale+OE | $4.06 | -52,485 | 824,918 | -6% | -$213,089 | |||||
2026-07-15 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.56 | +1,000 | 801,000 | 0% | +$1,555 | ||||||
| A | 2026-07-14 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% | S - Sale | $37.54 | -28,315 | 2,705,000 | -1% | -$1,063,033 | |||||
| D | 2026-07-15 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $33.99 | -4,000 | 174,209 | -2% | -$135,974 | |||||
2026-07-15 | CORT | Corcept Therapeutics Inc | Wilson James N | Dir | S - Sale | $88.30 | -10,000 | 1,484,543 | -1% | -$882,986 | ||||||
| D | 2026-07-15 | CORT | Corcept Therapeutics Inc | Mokari Atabak | CFO | S - Sale+OE | $87.71 | -40,000 | 16,130 | -71% | -$3,508,277 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |